Journal article

Health service use pathways associated with recovery of quality of life at 12-months for individual fracture sites: Analyses of the International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS)

Jason Talevski, Kerrie M Sanders, Ljoudmila Busija, Alison Beauchamp, Gustavo Duque, Fredrik Borgstrom, John A Kanis, Axel Svedbom, Amanda L Stuart, Sharon Brennan-Olsen

BONE | ELSEVIER SCIENCE INC | Published : 2021

Abstract

PURPOSE: We aimed to identify combinations of health service use specific to each major osteoporotic fracture (MOF) site - hip, distal forearm, vertebrae and humerus - associated with recovery of health-related quality of life (HRQoL) 12-months post-MOF. METHODS: Patients were 4126 adults aged ≥50 years with a MOF (1657 hip, 1354 distal forearm, 681 vertebral, 434 humerus) from the International Costs and Utilities Related to Osteoporotic fractures Study (Australia, Austria, Estonia, France, Italy, Lithuania, Mexico, Russia, Spain and the UK). HRQoL (pre-fracture and 12-months post-fracture) was measured using the EQ-5D-3L. Health service use data were collected via interviews and medical re..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC, of Australia)


Awarded by NHMRC Career Development Fellowship


Funding Acknowledgements

JT is supported by an Australian National Health and Medical Research Council (NHMRC, of Australia) Postgraduate Scholarship (1151089), and SB-O supported by a NHMRC Career Development Fellowship (1107510). On its international level, the ICUROS is sponsored by Amgen, Eli Lilly, Medtronic, Novartis, Sanofi-Aventis, Servier, and Pfizer. In Australia, the study was supported by the National Health and Medical Research Council with supplementary funding from Merck Pty Ltd. In Austria, the study was sponsored by Central Association of Austrian Social Security Institution, Austrian Society for Bone and Mineral Research (AuSBMR), Merck Sharp & Dohme, Servier GmbH, Medtronic GmbH, Amgen GmbH, Novartis GmbH, Nycomed GmbH, Roche GmbH, Sanofi-Aventis GmbH, and Daiichi-Sankyo GmbH. In Mexico, the study was supported by CONACyT. In Lithuania, the work was supported by the National Osteoporosis Center. In the USA, Amgen Inc., Ingenix Pharmaceutical Services, Eli Lilly and Company, Medtronic Spine LLC, and Pfizer (formerly Wyeth) sponsored the study. Hoffmann La Roche and Amgen provided support. In Estonia, the study was supported by the Estonian Science Foundation, and the Estonian Ministry of Education and Research. In Russia, the study was supported by Hoffmann La Roche, Amgen, and the Russian Osteoporosis Association.